Immunotherapy in Hodgkin Lymphoma: The Road Ahead

Research output: Contribution to journalReview article

Abstract

An extensive infiltrate of intratumoral immune cells is a hallmark of classic Hodgkin lymphoma (cHL) but these cells do result in an effective antitumor response. Immune checkpoint therapy, which activates ‘exhausted’ T cells, has been found to be highly effective in cHL, but responding patients commonly relapse. Combination approaches are currently being investigated but the assessment of benefit when adding immunotherapy is challenging. The pitfalls in designing combination studies derive from response endpoints that are difficult to measure, a lack of biomarkers that predict response, and a limited understanding of tumor biology. While progress in treating patients with cHL has been exceptional so far, further progress may require a review of clinical trial endpoints and a greater understanding of cHL biology.

Original languageEnglish (US)
Pages (from-to)380-386
Number of pages7
JournalTrends in Immunology
Volume40
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Hodgkin Disease
Immunotherapy
Biomarkers
Clinical Trials
T-Lymphocytes
Recurrence
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immunotherapy in Hodgkin Lymphoma : The Road Ahead. / Ansell, Stephen Maxted.

In: Trends in Immunology, Vol. 40, No. 5, 01.05.2019, p. 380-386.

Research output: Contribution to journalReview article

@article{004f9e8a0a314a36986636754653d366,
title = "Immunotherapy in Hodgkin Lymphoma: The Road Ahead",
abstract = "An extensive infiltrate of intratumoral immune cells is a hallmark of classic Hodgkin lymphoma (cHL) but these cells do result in an effective antitumor response. Immune checkpoint therapy, which activates ‘exhausted’ T cells, has been found to be highly effective in cHL, but responding patients commonly relapse. Combination approaches are currently being investigated but the assessment of benefit when adding immunotherapy is challenging. The pitfalls in designing combination studies derive from response endpoints that are difficult to measure, a lack of biomarkers that predict response, and a limited understanding of tumor biology. While progress in treating patients with cHL has been exceptional so far, further progress may require a review of clinical trial endpoints and a greater understanding of cHL biology.",
author = "Ansell, {Stephen Maxted}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.it.2019.03.003",
language = "English (US)",
volume = "40",
pages = "380--386",
journal = "Trends in Immunology",
issn = "1471-4906",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Immunotherapy in Hodgkin Lymphoma

T2 - The Road Ahead

AU - Ansell, Stephen Maxted

PY - 2019/5/1

Y1 - 2019/5/1

N2 - An extensive infiltrate of intratumoral immune cells is a hallmark of classic Hodgkin lymphoma (cHL) but these cells do result in an effective antitumor response. Immune checkpoint therapy, which activates ‘exhausted’ T cells, has been found to be highly effective in cHL, but responding patients commonly relapse. Combination approaches are currently being investigated but the assessment of benefit when adding immunotherapy is challenging. The pitfalls in designing combination studies derive from response endpoints that are difficult to measure, a lack of biomarkers that predict response, and a limited understanding of tumor biology. While progress in treating patients with cHL has been exceptional so far, further progress may require a review of clinical trial endpoints and a greater understanding of cHL biology.

AB - An extensive infiltrate of intratumoral immune cells is a hallmark of classic Hodgkin lymphoma (cHL) but these cells do result in an effective antitumor response. Immune checkpoint therapy, which activates ‘exhausted’ T cells, has been found to be highly effective in cHL, but responding patients commonly relapse. Combination approaches are currently being investigated but the assessment of benefit when adding immunotherapy is challenging. The pitfalls in designing combination studies derive from response endpoints that are difficult to measure, a lack of biomarkers that predict response, and a limited understanding of tumor biology. While progress in treating patients with cHL has been exceptional so far, further progress may require a review of clinical trial endpoints and a greater understanding of cHL biology.

UR - http://www.scopus.com/inward/record.url?scp=85063681387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063681387&partnerID=8YFLogxK

U2 - 10.1016/j.it.2019.03.003

DO - 10.1016/j.it.2019.03.003

M3 - Review article

C2 - 30948348

AN - SCOPUS:85063681387

VL - 40

SP - 380

EP - 386

JO - Trends in Immunology

JF - Trends in Immunology

SN - 1471-4906

IS - 5

ER -